

IHCP *bulletin*

INDIANA HEALTH COVERAGE PROGRAMS BT2023179 DECEMBER 28, 2023

Coverage removed for Pfizer and Moderna COVID-19 vaccination codes; replacement codes provided

Effective Oct. 31, 2023, the Centers for Medicare & Medicaid Services (CMS) ended coverage of any remaining Pfizer and Moderna coronavirus disease 2019 (COVID-19) vaccine and vaccine administration codes. As previously announced by the CMS, a more streamlined set of codes has been introduced for COVID-19 vaccine products and administration.

Effective immediately, for dates of service (DOS) on or after **Nov. 1, 2023**, the Indiana Health Coverage Programs (IHCP) will not reimburse providers for the COVID-19 vaccination codes listed in [Table 1](#). The codes in Table 1, as well as the codes previously announced as noncovered for DOS on or after April 18, 2023 (see *IHCP Bulletin BT202361*), were officially end-dated by the CMS effective Oct. 31, 2023. The only Current Procedural Terminology (CPT^{®1}) codes that the IHCP now covers for Pfizer and Moderna COVID-19 vaccine and vaccine administration are the new codes that were announced in [BT2023165](#) (listed as replacement procedure codes in Table 1 in this bulletin).



These changes will be reflected in the next regular update to the Professional Fee Schedule and Outpatient Fee Schedule, accessible from the [IHCP Fee Schedules](#) page at in.gov/medicaid/providers.

Updates will also be made to the following code tables, accessible from the [Code Sets](#) page at in.gov/medicaid/providers:

- *COVID-19 Vaccination Codes*
- *Family Planning Eligibility Program Codes*
- *Physician-Administered Drugs Carved Out of Managed Care and Reimbursable Outside the Inpatient Diagnosis-Related Group (DRG)*
- *Preventive Care Services Exempt From Copay for Healthy Indiana Plan and Presumptive Eligibility Adult*
- *Revenue Codes With Special Procedure Code Linkages*
- *Transportation Services Codes*

¹CPT copyright 2023 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

Table 1 – Pfizer and Moderna COVID-19 vaccination codes no longer covered for DOS on or after Nov. 1, 2023, along with replacement codes

End-dated procedure code	Description	Replacement procedure code
91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	91320
91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	91322
91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	91321
91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	91319
91316	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use	91321
91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	91318
0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 ml dosage, tris-sucrose formulation; single dose	90480
0124A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, additional dose	90480
0134A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, additional dose	90480
0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 ml dosage; first dose	90480
0142A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 ml dosage; second dose	90480
0144A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, additional dose	90480
0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 ml dosage, diluent reconstituted, tris-sucrose formulation; single dose	90480
0154A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, additional dose	90480
0164A	Intramuscular administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, additional dose	90480

Table 1 – Pfizer and Moderna COVID-19 vaccination codes no longer covered for DOS on or after Nov. 1, 2023, along with replacement codes (Continued)

End-dated procedure code	Description	Replacement procedure code
0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 ml dosage, diluent reconstituted, tris-sucrose formulation; first dose	90480
0172A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 ml dosage, diluent reconstituted, tris-sucrose formulation; second dose	90480
0173A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	90480
0174A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, additional dose	90480

QUESTIONS?

If you have questions about this publication, please contact Customer Assistance at 800-457-4584.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from the [IHCP Bulletins](#) page of the IHCP provider website at in.gov/medicaid/providers.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the [IHCP provider website](#) at in.gov/medicaid/providers.

